398
Views
13
CrossRef citations to date
0
Altmetric
Research Article

Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey

, , , , , , , , , , , , , , , , , , , & show all
Pages 841-847 | Received 14 Sep 2012, Accepted 03 May 2013, Published online: 17 Oct 2013

References

  • National Center for Complementary and Alternative Medicine (NCCAM). What is CAM? Available from: http://nccam.nih.gov/health/whatiscam/
  • Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 1998;83:777–782.
  • Patterson RE, Neuhouser ML, Hedderson MM, et al. Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. J Altern Complement Med 2002;8:477–485.
  • Richardson MA, Sanders T, Palmer JL, et al. Complementary /alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000;18:2505–2514.
  • Molassiotis A, Fernandez-Ortega P, Pud D, et al. Use of complementary and alternative medicine in cancer patients; a European survey. Ann Oncol 2005;16:655–663.
  • Molassiotis A, Margulies A, Fernandez-Ortega P, et al. Complementary and alternative medicine use in patients with hematological malignancies in Europe. Complement Ther Clin Pract 2005;11:105–110.
  • Gupta M, Shafiq N, Kumari S, et al. Patterns and perceptions of complementary and alternative medicine (CAM) among leukaemia patients visiting hematology clinic of a north Indian tertiary care hospital. Pharmacoepidemiol Drug Saf 2002;11:671–676.
  • Ben-Arye E, Attias S, Tadmor T, et al. Herbs in hemato-oncological care: an evidence-based review of data on efficacy, safety, and drug interactions. Leuk Lymphoma 2010;51:1414–1423.
  • Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804–815.
  • Gribben JG. How I treat CLL up front. Blood 2010;115:187–197.
  • Hensel M, Zoz M, Ho AD. Complementary and alternative medicine in patients with chronic lymphocytic leukemia. Support Care Cancer 2009;17:47–52.
  • Menniti-Ippolito F, Gargiulo L, Bologna E, et al. Use of unconventional medicine in Italy: a nation-wide survey. Eur J Clin Pharmacol 2002;58:61–64.
  • Frass M, Strassl RP, Friehs H, et al. Use and acceptance of complementary and alternative medicine among the general population and medical personnel: a systematic review. Ochsner J 2012;12:45–56.
  • Johannessen H, von Bornemann HJ, Pasquarelli E, et al. Prevalence in the use of complementary medicine among cancer patients in Tuscany, Italy. Tumori 2008;94:406–410.
  • Saini A, Berruti A, Capogna S, et al. Prevalence of complementary/alternative medicines (CAMs) in a cancer population in northern Italy receiving antineoplastic treatments and relationship with quality of life and psychometric features. Qual Life J 2011;20: 683–690.
  • Shanafelt TD, Call TG, Zent CS, et al. Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer 2013;119:363–370.
  • Rosenthal DS, Dean-Clower E. Integrative medicine in hematology/oncology: benefits, ethical considerations, and controversies. Hematology 2005;1:491–497.
  • Golden EB, Lam PY, Kardosh A, et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 2009;113:5927–5937.
  • Shah JJ, Kuhn DJ, Orlowski RZ. Bortezomib and EGCG: no grean tea for you?. Blood 2009;113;5695–5696.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.